A Phase 1 interventional study of Enlicitide in Hepatic Insufficiency and Hepatic Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hepatic Insufficiency by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Hepatic Insufficiency · Merck & Co., Inc.
Among the 10 studies in Hepatic Insufficiency by Merck & Co., Inc, this one is the 4th largest by enrollment, is the only one that started in 2024, is one of 10 in phase 1, and was the 9th registered.
113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.
Browse Hepatic Insufficiency studies →1 of the 10 studies in Hepatic Insufficiency by Merck & Co., Inc is open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC
Ages 18–75 · Healthy volunteers
Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 29 across 100 interventional studies indexed under Hepatic Insufficiency.
Median enrollment 20 across the 10 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
1 of the studies in Hepatic Insufficiency by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05093972Merck Sharp & Dohme LLCUlonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014) | 2027-06-29 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Hepatic Insufficiency by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood. Enlicitide decanoate will be called "enlicitide" from this point forward,
The purpose of this study is to learn what happens to enlicitide in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to enlicitide in the body when it is given to people with hepatic impairment (HI- meaning the liver does not work properly) and people who are in good health.
This study will have 2 parts. In Part 1, enlicitide will be given to people with moderate HI and people who are in good health. After Part 1, researchers may decide to include people who have mild HI and compare what happens to enlicitide in the body with people who are in good health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
All participants:
Participants with moderate or mild HI:
Healthy Control Participants:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
All participants:
Participants with moderate or mild HI:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose of enlicitide on Day 1
Drug: Enlicitide
Participants will receive a single oral dose of enlicitide on Day 1
Drug: Enlicitide
Participants will receive a single oral dose of enlicitide on Day 1
Drug: Enlicitide
Oral tablet
Also known as: enlicitide decanoate, MK-0616/sodium caprate
Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Enlicitide
Blood samples were collected at pre-specified time points to determine the AUC0-inf of enlicitide in plasma. AUC0-inf was defined as AUC0-last + (Cest,last/λz) where Cest, last was the estimated last measurable concentration, and λz was the apparent first-order terminal elimination rate constant.
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose
Maximum Concentration (Cmax) of Enlicitide
Blood samples were collected at pre-specified time points to determine the Cmax of enlicitide in participant's plasma. Cmax was defined as the maximum observed concentration of enlicitide in plasma after the administration of a given dose.
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose
Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of Enlicitide
Blood samples were collected at pre-specified time points to determine the AUC0-24 of encilitide. AUC0-24 of encilitide was defined as the area under the concentration-time curve from time 0 to the 24 hours after the dosing of encilitide.
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, and 24 hours postdose
Area Under the Concentration Versus Time Curve From Time 0 to Last (AUC0-last) of Enlicitide in Plasma
Blood samples were collected at pre-specified time points to determine the AUC0-last of enlicitide in participant's plasma. AUC0 to last of enlicitide was defined as the area under the concentration-time curve from time 0 to the time of the last quantifiable (above lower limit of quantitation) concentration. AUC0-last was calculated using noncompartmental analysis.
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose
Time to Maximum (Tmax) Observed Plasma Drug Concentration of Enlicitide
Blood samples were collected at pre-specified time points to determine the tmax of enlicitide in participant's plasma. Tmax was defined as time to the maximum concentration of enlicitide reached.
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose
Apparent Terminal Half-life (t1/2) of Enlicitide
Blood samples were collected at pre-specified timepoints to determine the t1/2 of enlicitide. t1/2 was defined as the time required to divide the enlicitide plasma concentration by two after reaching pseudo-equilibrium, following a single dose of enlicitide.
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose
Apparent Clearance (CL/F) of Enlicitide
Blood samples were collected at pre-specified timepoints to determine the CL/F of enlicitide. CL/F was the apparent total clearance of enlicitide in plasma over time, assessed as the rate at which enlicitide was removed from the plasma.
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose
Apparent Volume of Distribution During Terminal Phase (Vz/F) of Enlicitide
Blood samples were collected at pre-specified timepoints to determine the Vz/F of enlicitide. Vz/F was the apparent volume of distribution of enlicitide between the plasma and the rest of the body, after dose, assessed as the total volume of enlicitide that would need to be uniformly distributed to achieve the desired plasma drug concentration.
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose
Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment-emergent if the onset date and time is at the time of or after the first study drug administration. The number of participants who experienced a TEAE were reported.
Time frame: Up to approximately 6 weeks
Number of Participants Who Experienced An Adverse Event (AE)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported.
Time frame: Up to approximately 6 weeks
Number of Participants Who Discontinued Study Due to an AE
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who discontinued from the study due to an AE were reported..
Time frame: Up to approximately 6 weeks
Participants with chronic, stable hepatic insufficiency (HI) meeting a Child-Pugh score of 7 - 9 corresponding to moderate HI were enrolled.
| Milestone | Moderate Hepatic Impairment (HI) | Healthy Controls |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
Blood samples were collected at pre-specified time points to determine the AUC0-24 of encilitide. AUC0-24 of encilitide was defined as the area under the concentration-time curve from time 0 to the 24 hours after the dosing of encilitide.
| nM•hr | Moderate Hepatic Impairment (HI) | Healthy Controls |
|---|---|---|
| Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of Enlicitide | 131 ± 35.9 | 149 ± 32.4 |
Blood samples were collected at pre-specified time points to determine the AUC0-last of enlicitide in participant's plasma. AUC0 to last of enlicitide was defined as the area under the concentration-time curve from time 0 to the time of the last quantifiable (above lower limit of quantitation) concentration. AUC0-last was calculated using noncompartmental analysis.
| nM•hr | Moderate Hepatic Impairment (HI) | Healthy Controls |
|---|---|---|
| Area Under the Concentration Versus Time Curve From Time 0 to Last (AUC0-last) of Enlicitide in Plasma | 486 ± 38.8 | 506 ± 42.7 |
Blood samples were collected at pre-specified time points to determine the tmax of enlicitide in participant's plasma. Tmax was defined as time to the maximum concentration of enlicitide reached.
| Hour | Moderate Hepatic Impairment (HI) | Healthy Controls |
|---|---|---|
| Time to Maximum (Tmax) Observed Plasma Drug Concentration of Enlicitide | 0.75 (0.50 to 24.13) | 1.50 (0.50 to 24.28) |
Blood samples were collected at pre-specified timepoints to determine the t1/2 of enlicitide. t1/2 was defined as the time required to divide the enlicitide plasma concentration by two after reaching pseudo-equilibrium, following a single dose of enlicitide.
| Hour | Moderate Hepatic Impairment (HI) | Healthy Controls |
|---|---|---|
| Apparent Terminal Half-life (t1/2) of Enlicitide | 49.3 ± 14.4 | 48.0 ± 20.4 |
Blood samples were collected at pre-specified timepoints to determine the CL/F of enlicitide. CL/F was the apparent total clearance of enlicitide in plasma over time, assessed as the rate at which enlicitide was removed from the plasma.
| Liters/Hour | Moderate Hepatic Impairment (HI) | Healthy Controls |
|---|---|---|
| Apparent Clearance (CL/F) of Enlicitide | 23.9 ± 36.7 | 23.1 ± 43.8 |
Blood samples were collected at pre-specified timepoints to determine the Vz/F of enlicitide. Vz/F was the apparent volume of distribution of enlicitide between the plasma and the rest of the body, after dose, assessed as the total volume of enlicitide that would need to be uniformly distributed to achieve the desired plasma drug concentration.
| Liters | Moderate Hepatic Impairment (HI) | Healthy Controls |
|---|---|---|
| Apparent Volume of Distribution During Terminal Phase (Vz/F) of Enlicitide | 1700 ± 47.8 | 1600 ± 32.8 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment-emergent if the onset date and time is at the time of or after the first study drug administration. The number of participants who experienced a TEAE were reported.
| Participants | Moderate Hepatic Impairment (HI) | Healthy Controls |
|---|---|---|
| Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE) | 0 | 0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported.
| Participants | Moderate Hepatic Impairment (HI) | Healthy Controls |
|---|---|---|
| Number of Participants Who Experienced An Adverse Event (AE) | 0 | 0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who discontinued from the study due to an AE were reported..
| Participants | Moderate Hepatic Impairment (HI) | Healthy Controls |
|---|---|---|
| Number of Participants Who Discontinued Study Due to an AE | 0 | 0 |
Blood samples were collected at pre-specified time points to determine the AUC0-inf of enlicitide in plasma. AUC0-inf was defined as AUC0-last + (Cest,last/λz) where Cest, last was the estimated last measurable concentration, and λz was the apparent first-order terminal elimination rate constant.
| nM·hr | Moderate Hepatic Impairment (HI) | Healthy Controls |
|---|---|---|
| Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Enlicitide | 540 ± 36.7 | 559 ± 43.8 |
Blood samples were collected at pre-specified time points to determine the Cmax of enlicitide in participant's plasma. Cmax was defined as the maximum observed concentration of enlicitide in plasma after the administration of a given dose.
| nM | Moderate Hepatic Impairment (HI) | Healthy Controls |
|---|---|---|
| Maximum Concentration (Cmax) of Enlicitide | 9.07 ± 52.6 | 8.81 ± 49.2 |
Collected over Up to approximately 6 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Moderate Hepatic Impairment (HI) | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Healthy Controls | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Age, Continuous(Years) | Moderate Hepatic Impairment (HI) | Healthy Controls | Total |
|---|---|---|---|
| Mean | 60.3 ± 5.36 | 58.7 ± 6.75 | 59.5 ± 5.99 |
| Sex: Female, Male(Participants) | Moderate Hepatic Impairment (HI) | Healthy Controls | Total |
|---|---|---|---|
| Female | 3 | 4 | 7 |
| Male | 7 | 6 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Moderate Hepatic Impairment (HI) | Healthy Controls | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 6 | 15 |
| Not Hispanic or Latino | 1 | 4 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Moderate Hepatic Impairment (HI) | Healthy Controls | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 10 | 9 | 19 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Sep 2024 to primary completion in May 2025, 7 months.
Results were first posted in May 2026, 1 year after primary completion.
Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 7 months is below that.
Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enlicitide